Clinical data | |
---|---|
Trade names | H.O.P, Hydroxyprogesterone, Lutogil A.P., Lutogyl A.P., others |
Other names | OHPH; Hydroxyprogesterone enanthate; OHPE; 17α-Hydroxyprogesterone heptanoate; 17α-Hydroxyprogesterone heptylate; 17α-Hydroxypregn-4-ene-3,20-dione 17α-heptanoate; 17α-Heptyloylpregn-4-ene-3,20-dione |
Routes of administration | Intramuscular injection |
Drug class | Progestogen; Progestin; Progestogen ester |
ATC code | |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.022.724 |
Chemical and physical data | |
Formula | C28H42O4 |
Molar mass | 442.640 g·mol−1 |
3D model ( JSmol) | |
| |
|
Hydroxyprogesterone heptanoate (OHPH), also known as hydroxyprogesterone enanthate (OHPE) and sold under the brand names H.O.P., Lutogil A.P., and Lutogyl A.P. among others, is a progestin medication used for progestogenic indications. [1] [2] [3] [4] It has been formulated both alone and in together with estrogens, androgens/ anabolic steroids, and other progestogens in several combination preparations (brand names Tocogestan, Trioestrine Retard, and Triormon Depositum). [4] [5] [6] [7] [8] [9] [10] OHPH is given by injection into muscle at regular intervals. [11] [9]
OHPH is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. [12] [13] [14] It appears to have similar pharmacology to that of the closely related medication hydroxyprogesterone caproate (OHPC). [15] [16] [17]
OHPH was first described by 1954 [16] and was introduced for medical use by 1957. [6] It has been used clinically in France and Monaco in the past but is no longer marketed. [2] [3] [4]
OHPH is a progestogen and was used in situations in which progestogens were indicated. [12] [13] [14]
OHPH was provided as a 125 mg/1 mL oil solution for use by intramuscular injection. [3] [11] In addition to single-drug preparations, OHPH has also been used in a number of multi-drug formulations. [4] [5] [6] [7] [8] [9] [10] It was used in Tocogestan, a combination of 50 mg progesterone, 200 mg OHPH, and 250 mg α-tocopherol palmitate ( vitamin E) in oil solution for use by intramuscular injection. [18] [4] [5] It was also used in Triormon Depositum ( estradiol dibutyrate, testosterone caproate, and OHPH) and Trioestrine Retard ( estradiol diundecylate, testosterone cyclohexylpropionate, and OHPH). [6] [7] OHPH was a component of the experimental preparation Trophobolene (or Trophoboline), which also contained estrapronicate (estradiol nicotinate propionate) and nandrolone undecanoate, as well. [8] [9] [10]
OHPH is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. [15] [12] [13] [14] The progestogenic potency of OHPH in the uterus is equal to or greater than that of progesterone when administered by subcutaneous injection in animals. [15] [16] [17] Its potency in animals likewise appears to be similar to that of hydroxyprogesterone caproate. [15] [16] [17]
OHPH shows a pronounced depot effect when administered by subcutaneous injection in animals, similarly to the closely related medication hydroxyprogesterone caproate. [15] [16] The oral activity of OHPH in animals does not appear to have been assessed. [15]
OHPH, also known as hydroxyprogesterone enanthate (OHPE), [19] as well as 17α-hydroxyprogesterone heptanoate or 17α-hydroxypregn-4-ene-3,20-dione 17α-heptanoate, is a synthetic pregnane steroid and a derivative of progesterone and 17α-hydroxyprogesterone. [1] [2] It is a progestogen ester; specifically, it is the C17α heptanoate (enanthate) ester of 17α-hydroxyprogesterone. [1] [2] Analogues of OHPH include the more well-known medications hydroxyprogesterone acetate and hydroxyprogesterone caproate (hydroxyprogesterone hexanoate). [1] [2] The C3 benzilic acid hydrazone of OHPH, hydroxyprogesterone heptanoate benzilic acid hydrazone (OHPHBH), is known and has been studied in animals. [20] [21] In terms of chemical structure, OHPH is very similar to hydroxyprogesterone caproate, differing from it only in having one additional carbon in its fatty acid ester chain. [1] [2]
OHPH was first described, along with hydroxyprogesterone caproate and hydroxyprogesterone acetate, by Karl Junkmann of Schering AG in 1954. [16] [19] It was introduced for medical use by 1957. [6] OHPH was commercialized by Roussel and Théramex, and has been used clinically in France and Monaco but is no longer marketed. [2] [3] [4]
OHPH has been marketed alone under a number of brand names including H.O.P, Hydroxyprogesterone, Lutogil A.P., and Lutogyl A.P. [1] [2] [3] [4]
OHPH was previously marketed in France and Monaco but is no longer available. [2] [3] [22]
Triormon depositum (estradiol dibutyrate 3, testosterone caprylate 50, and hydroxyprogesterone heptanoate 30 mg.), administered in castor oil-benzyl benzoate soln. or polyvinylpyrrolidone suspension to 21 women in climacteric, was followed by estradiol, pregnanediol, and 17-keto steroid urinary curves, most with a peak at the 4th day, and approaching starting values at the 8-10th day. The therapeutic efficacy of the drug was satisfactory.
The patients (females) received intramuscularly, every 10 days for 2-3 months, estradiol diundecyleate 2.25, testosterone cyclohexylpropionate 67.5, and hydroxyprogesterone heptylate 100 mg. ("trioestrine retard"). Their av. calcuria decreased 30.5% (0-69%) and asthenia, anorexia, and muscular activity improved.
Progestogens. [...] Hydroxyprogesterone heptanoate. Hydroxyprogesterone (Theramex). Oily solution for injection.
Clinical data | |
---|---|
Trade names | H.O.P, Hydroxyprogesterone, Lutogil A.P., Lutogyl A.P., others |
Other names | OHPH; Hydroxyprogesterone enanthate; OHPE; 17α-Hydroxyprogesterone heptanoate; 17α-Hydroxyprogesterone heptylate; 17α-Hydroxypregn-4-ene-3,20-dione 17α-heptanoate; 17α-Heptyloylpregn-4-ene-3,20-dione |
Routes of administration | Intramuscular injection |
Drug class | Progestogen; Progestin; Progestogen ester |
ATC code | |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.022.724 |
Chemical and physical data | |
Formula | C28H42O4 |
Molar mass | 442.640 g·mol−1 |
3D model ( JSmol) | |
| |
|
Hydroxyprogesterone heptanoate (OHPH), also known as hydroxyprogesterone enanthate (OHPE) and sold under the brand names H.O.P., Lutogil A.P., and Lutogyl A.P. among others, is a progestin medication used for progestogenic indications. [1] [2] [3] [4] It has been formulated both alone and in together with estrogens, androgens/ anabolic steroids, and other progestogens in several combination preparations (brand names Tocogestan, Trioestrine Retard, and Triormon Depositum). [4] [5] [6] [7] [8] [9] [10] OHPH is given by injection into muscle at regular intervals. [11] [9]
OHPH is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. [12] [13] [14] It appears to have similar pharmacology to that of the closely related medication hydroxyprogesterone caproate (OHPC). [15] [16] [17]
OHPH was first described by 1954 [16] and was introduced for medical use by 1957. [6] It has been used clinically in France and Monaco in the past but is no longer marketed. [2] [3] [4]
OHPH is a progestogen and was used in situations in which progestogens were indicated. [12] [13] [14]
OHPH was provided as a 125 mg/1 mL oil solution for use by intramuscular injection. [3] [11] In addition to single-drug preparations, OHPH has also been used in a number of multi-drug formulations. [4] [5] [6] [7] [8] [9] [10] It was used in Tocogestan, a combination of 50 mg progesterone, 200 mg OHPH, and 250 mg α-tocopherol palmitate ( vitamin E) in oil solution for use by intramuscular injection. [18] [4] [5] It was also used in Triormon Depositum ( estradiol dibutyrate, testosterone caproate, and OHPH) and Trioestrine Retard ( estradiol diundecylate, testosterone cyclohexylpropionate, and OHPH). [6] [7] OHPH was a component of the experimental preparation Trophobolene (or Trophoboline), which also contained estrapronicate (estradiol nicotinate propionate) and nandrolone undecanoate, as well. [8] [9] [10]
OHPH is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. [15] [12] [13] [14] The progestogenic potency of OHPH in the uterus is equal to or greater than that of progesterone when administered by subcutaneous injection in animals. [15] [16] [17] Its potency in animals likewise appears to be similar to that of hydroxyprogesterone caproate. [15] [16] [17]
OHPH shows a pronounced depot effect when administered by subcutaneous injection in animals, similarly to the closely related medication hydroxyprogesterone caproate. [15] [16] The oral activity of OHPH in animals does not appear to have been assessed. [15]
OHPH, also known as hydroxyprogesterone enanthate (OHPE), [19] as well as 17α-hydroxyprogesterone heptanoate or 17α-hydroxypregn-4-ene-3,20-dione 17α-heptanoate, is a synthetic pregnane steroid and a derivative of progesterone and 17α-hydroxyprogesterone. [1] [2] It is a progestogen ester; specifically, it is the C17α heptanoate (enanthate) ester of 17α-hydroxyprogesterone. [1] [2] Analogues of OHPH include the more well-known medications hydroxyprogesterone acetate and hydroxyprogesterone caproate (hydroxyprogesterone hexanoate). [1] [2] The C3 benzilic acid hydrazone of OHPH, hydroxyprogesterone heptanoate benzilic acid hydrazone (OHPHBH), is known and has been studied in animals. [20] [21] In terms of chemical structure, OHPH is very similar to hydroxyprogesterone caproate, differing from it only in having one additional carbon in its fatty acid ester chain. [1] [2]
OHPH was first described, along with hydroxyprogesterone caproate and hydroxyprogesterone acetate, by Karl Junkmann of Schering AG in 1954. [16] [19] It was introduced for medical use by 1957. [6] OHPH was commercialized by Roussel and Théramex, and has been used clinically in France and Monaco but is no longer marketed. [2] [3] [4]
OHPH has been marketed alone under a number of brand names including H.O.P, Hydroxyprogesterone, Lutogil A.P., and Lutogyl A.P. [1] [2] [3] [4]
OHPH was previously marketed in France and Monaco but is no longer available. [2] [3] [22]
Triormon depositum (estradiol dibutyrate 3, testosterone caprylate 50, and hydroxyprogesterone heptanoate 30 mg.), administered in castor oil-benzyl benzoate soln. or polyvinylpyrrolidone suspension to 21 women in climacteric, was followed by estradiol, pregnanediol, and 17-keto steroid urinary curves, most with a peak at the 4th day, and approaching starting values at the 8-10th day. The therapeutic efficacy of the drug was satisfactory.
The patients (females) received intramuscularly, every 10 days for 2-3 months, estradiol diundecyleate 2.25, testosterone cyclohexylpropionate 67.5, and hydroxyprogesterone heptylate 100 mg. ("trioestrine retard"). Their av. calcuria decreased 30.5% (0-69%) and asthenia, anorexia, and muscular activity improved.
Progestogens. [...] Hydroxyprogesterone heptanoate. Hydroxyprogesterone (Theramex). Oily solution for injection.